Pay in 4 interest-free payments of $7.43 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
2016 Jul;59(7):1412-21
Conflict of interest Author AA has received consulting fees from AbbVie, Allergan, Amgen, Arena, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, MSD, Mylan, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sandoz and Takeda
Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
Following the screening of one abstract, no full texts were reviewed (access was restricted due to payment requirements), and no articles were included in this narrative review
Others describe products that felt like expensive water
US$ 27.44
US$ 27.32
US$ 29.65
US$ 27.53
US$ 26.04
